References
- Durán Graeff L, Seidel D, Vehreschild MJGT, et al.; FungiScope Group. Invasive infections due to Saprochaete and Geotrichum species: report of 23 cases from the FungiScope registry. Mycoses. 2017;60(4):273–279. doi:10.1111/myc.12595.
- Stanzani M, Cricca M, Sassi C, et al. Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: a report of a monocentric outbreak and review of the literature. Mycoses. 2019;62(12):1100–1107. doi:10.1111/myc.12978.
- Pavone P, Oliva A, Raponi G, et al. Disseminated fungal infection due to Saprochaete clavata in a kidney transplant recipient. J Mycol Med. 2019;29(3):278–281. doi:10.1016/j.mycmed.2019.06.002.
- Buchta V, Bolehovská R, Hovorková E, Cornely OA, Seidel D, Žák P. Saprochaete clavata invasive infections – a new threat to hematological-oncological patients. Front Microbiol. 2019;10:2196. doi:10.3389/fmicb.2019.02196.
- Vaux S, Criscuolo A, Desnos-Ollivier M, et al., Geotrichum Investigation Group. Multicenter outbreak of infections by Saprochaete clavata, an unrecognized opportunistic fungal pathogen. mBio. 2014;5(6). doi:10.1128/mBio.02309-14.
- Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. doi:10.1093/cid/civ933.
- Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O. European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group, European Confederation of Medical Mycology. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014;20(Suppl 3):76–98. doi:10.1111/1469-0691.12360.
- O’Day DM, Head WS, Robinson RD, Stern WH, Freeman JM. Intraocular penetration of systemically administered antifungal agents. Curr Eye Res. 1985;4(2):131–134. doi:10.3109/02713688508999978.
- Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother. 2002;46(12):3719–3723. doi:10.1128/aac.46.12.3719-3723.2002.
- Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol. 2004;122(1):42–47. doi:10.1001/archopht.122.1.42.
- Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46(2):171–179. doi:10.1093/jac/46.2.171.
- Lempers VJ, Meuwese E, Mavinkurve-Groothuis AM, et al. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. Med Mycol. 2019;57(8):937–943. doi:10.1093/mmy/myz006.
- Shen Y-C, Wang M-Y, Wang C-Y, et al. Clearance of intravitreal voriconazole. Invest Ophthalmol Vis Sci. 2007;48(5):2238–2241. doi:10.1167/iovs.06-1362.
- Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology. 1985;92(11):1601–1605. doi:10.1016/S0161-6420(85)33838-1.
- Paulus YM, Cheng S, Karth PA, Leng T. Prospective trial of endogenous fungal endophtalmitis and chorioretinitis rates, clinical course, and outcomes in patients with fungemia. Retina (Philadelphia, Pa). 2016;36(7):1357–1363. doi:10.1097/IAE.0000000000000919.
- Myint T, Dykhuizen MJ, McDonald CH, Ribes JA. Post operative fungal endopthalmitis due to Geotrichum candidum. Med Mycol Case Rep. 2015;10:4–6. doi:10.1016/j.mmcr.2015.11.001.
- Rota N, Danese C, Menchini F, et al. Fungal endogenous endophthalmitis secondary to magnusiomyces capitatus. Case Rep Ophthalmol. 2019;10(2):292–298. doi:10.1159/000502412.
- Shah A. Magnusiomyces capitatus: a new and emerging pathogen linked to keratomycosis. DJO. 2017;23(3):75. doi:10.5693/djo.02.2017.04.001.